# Spyre Therapeutics, Inc. (SYRE) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Spyre Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/SYRE/mda/fy2025/): filed 2026-02-19; accession 0001636282-26-000020 (https://www.sec.gov/Archives/edgar/data/1636282/000163628226000020/syre-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/SYRE/mda/fy2024/): filed 2025-02-27; accession 0001636282-25-000020 (https://www.sec.gov/Archives/edgar/data/1636282/000163628225000020/syre-20241231.htm)
- [FY 2023 MD&A](/company/SYRE/mda/fy2023/): filed 2024-02-29; accession 0001636282-24-000005 (https://www.sec.gov/Archives/edgar/data/1636282/000163628224000005/syre-20231231.htm)
- [FY 2022 MD&A](/company/SYRE/mda/fy2022/): filed 2023-03-02; accession 0000950170-23-005705 (https://www.sec.gov/Archives/edgar/data/1636282/000095017023005705/agle-20221231.htm)
- [FY 2021 MD&A](/company/SYRE/mda/fy2021/): filed 2022-03-08; accession 0001564590-22-008995 (https://www.sec.gov/Archives/edgar/data/1636282/000156459022008995/agle-10k_20211231.htm)

Back to /company/SYRE/